| Sequenom Charged With Faking It Derek Lowe submits: I wrote here about Sequenom (SQNM), a company which claimed to have developed an in vitro test for Downs Syndrome. The whole story dissolved into a heap of lawsuits, allegations of fraud, questions about whether Sequenom ever had such a test at all, and other craziness. Now the SEC has charged a former executive of the company with lying to investors. Elizabeth Dragon publicly touted the accuracy of the company's test several times, in front of large groups, before the roof came in. Here's the official complaint, and it's most interesting reading:Complete Story » seekingalpha.com |
PPD Expands cGMP Laboratory Services in North America (Business Wire) WILMINGTON, N.C.----PPD, Inc. today announced it has expanded its cGMP laboratory testing services into Wayne, Pa., to meet growing client demand for these services from pharmaceutical and biotechnology companies located in the northeastern United States. us.rd.yahoo.com |
FDA Panel Backs Cymbalta for Chronic Pain An FDA advisory panel narrowly backed an effort by Lilly to expand use of its antidepressant Cymbalta as a treatment for chronic pain. online.wsj.com |
Six Reasons to Like Pluristem Therapeutics M.E. Garza submits: I am recommending that readers take a look at Pluristem Therapeutics (Nasdaq: PSTI), a cell therapy company which obtains its cells from the placenta, or after-birth, which comes after the baby’s birth. Accordingly, Pluristem Therapeutics provides the solution to the embryonic stem cell controversy since Pluristem’s cells are not embryonic – in fact, Pluristem does not harm or even touch the donor to obtain its cells. Pluristem Therapeutics gets its cells from what has been designated as medical waste until now. Complete Story » seekingalpha.com |
Cord Blood America Revenues Up 14 Percent in Third Quarter 2010 [PR Newswire] - Cord Blood America, Inc. , the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, today said revenues for the third quarter ended September 30, 2010, increased 14 percent to $958,449 compared to $838,238 in the same period in 2009. Â us.rd.yahoo.com |